Get your free ETF data sample from our comprehensive offerings. Start your free trial→
Help us improve your experience. Please confirm your investor type:
Compare ETFs Easily
The Ultimate ETF Comparison Tool - Try Now!
Analyze up to 5 ETFs side-by-side and gain instant insights on performance, fees, holdings, and more to make data-driven investment decisions.
SBIO ETF · Invesco NASDAQ Biotech UCITS ETF
The SBIO Exchange Traded Fund (ETF) is provided by Invesco. It is built to track an index: NASDAQ Biotechnology Index. This ETF provides synthetic exposure, by owning its shares you earn the return of the index indirectly through the use of derivatives or a swap (i.e. a contract with a financial institution which delivers the return of the index). The dividend policy is capitalization.
Last update Yesterday at 8:00 AM UTC
LIVE
CLOSED
This fund is part ofUS Health Care1M perf.-3.64%
Last price
$59.43
1M perf.
-1.90%
1M flows
-€4.8M
AuM
€362M
E/R
0.4%
Rating
ESG Consensus®
SBIO
$59.43
Performance & flows
Segment for quartile rank
December 12, 2025 → March 12, 2026
Create a free account to view the flows graph
SBIO
$59.80
+0.65%
US Health Care
-1.91%
Historic performance and flows
| 1M | 3M | 1Y | 3Y | 5Y | MTD | QTD | YTD | ||
|---|---|---|---|---|---|---|---|---|---|
| Perf. | -1.90%  | +0.65% | +29.42% | +45.44% | +20.37%  | -4.89% | +0.69% | +0.69% | |
| Flows |
Key fund info
Segment for quartile rank
Main characteristics
More details
NAV
3/12/2026
$59.80
1D NAV change
-2.70%
Dividend policy
Replication method
Indirect
Replication model
Unfunded swap
No. of holdings
262
Inception date
11/7/2014
Jurisdiction
Ireland
Distribution
Netherlands
Norway
Portugal
Ireland
Italy
Legal structure
Open-end Investment Company
Base currency
USD
Classification
Investment strategy
The Invesco NASDAQ Biotech UCITS ETF Acc aims to provide the performance of the NASDAQ Biotechnology Index, after fees. The index comprises biotechnology and pharmaceuticals companies (as defined by ICB) listed on the NASDAQ Stock Market. Stocks are filtered to meet minimum market capitalisation and liquidity requirements. They are then weighted by modified market capitalisation: the largest five constituents are capped at 8%; the remaining constituents are capped at 4%. The index is rebalanced quarterly and reviewed annually in December.
Tax optimisation
PEA
France
UK Reporting Status
United Kingdom
Create a free Trackinsight Essentials account to unlock insights
Access exclusive metrics and features to support your investment decisions.
Built for professionals: access exclusive fund metrics and selection tools in Trackinsight Enterprise.
Enterprise Fund page features include:
Legal documents
Powerful buy-list integration
Fund data exports
Advanced risk metrics
Advanced replication analysis
Advanced exposure look-through
Upload your own internal metrics
Custom data feature
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseAdvertisement
Risk profile
Segment for quartile rank
Historical risk/return profile
| 3M | 1Y | 3Y | 5Y | |
|---|---|---|---|---|
| Returns | +0.65% | +29.42% | +45.44% | +20.37% |
| Volatility | ||||
| Perf./Volatility | ||||
| Max drawdown |
Create a free account to view risk/return table
Synthetic Risk and Reward Indicator (SRRI)
UCITS
1
2
3
4
5
6
7
PRIIPS
1
2
3
4
5
6
7
Built for professionals: access exclusive risk metrics in Trackinsight Enterprise.
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseExposure
Exposure based on a proxy
More info
Countries
USA
93.74%
United Kingdom
1.47%
Ireland
1.30%
Bermuda
1.16%
Unavailable
0.11%
Other
2.22%
Sectors
Health Care
85.79%
Unavailable
14.19%
Diversification
Exposure based on a proxy
More info
Total weight of top 15 holdings out of 262
Top 15 holdings
Data as of January 31, 2026
Exposure based on a proxy
More info
GILEAD SCIENCES
VERTEX PHARMACEUTICALS
AMGEN-T
REGENERON PHARMACEUTICALS
ALNYLAM PHARMACEUTICALS
INSMED
BIOGEN INC
US04016X1019
Create a free account to view top holdings
ILLUMINA
UTD THERAPEUT
INCYTE
REVOLUTION MEDICINES INC
MODERNA INC
ROYALTY PHARMA
MEDPACE HOLDINGS INC
Create a free account to view top holdings
Built for professionals: access exclusive exposure metrics in Trackinsight Enterprise.
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseSustainability
Integrates ESG criteria
No
SDG
Built for professionals: access exclusive sustainability metrics in Trackinsight Enterprise.
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseReplication
Trackinsight replication rating:
Replication quality
Calculated over 12m, as of February 27, 2026
Tracking error
Tracking difference
Replication information
Index
NASDAQ Biotechnology Total Return Index - USD
Index ticker
XNBI Index
Index dividend policy
GTR
Replication method
Replication model
Built for professionals: access exclusive replication metrics in Trackinsight Enterprise.
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseIssuer
Invesco
Invesco ID Card
Number of funds
631
Total AuM
€846.61B
Expense ratio range
0.04% - 5.39%
Average expense ratio
0.3562%
Top 5 funds by Invesco
| AuM | ||
|---|---|---|
QQQ | Invesco QQQ ETF | €334.28B |
RSP | Invesco S&P 500® Equal Weight ETF | €73.51B |
QQQM | Invesco NASDAQ 100 ETF | €60.56B |
SPXS | Invesco S&P 500 UCITS ETF | €30.51B |
SGLD | Invesco Physical Gold USD ETC | €28.5B |
Frequently asked questions about SBIO
What does Invesco NASDAQ Biotech UCITS ETF, SBIO, invest in?
SBIO is a Passive ETF. This ETF provides exposure to US Equities.
Which benchmark or index does SBIO replicate?
SBIO tracks the NASDAQ Biotechnology Total Return Index - USD, through a unfunded swap replication method.
What is the Total Expense ratio (TER) of SBIO?
SBIO carries a total expense ratio (TER) of 0.4%, indicating the annual cost for holding the fund.
When was SBIO launched?
SBIO was introduced to the market on November 7, 2014. It trades on Netherlands, among other exchanges
Who is the ETF issuer of SBIO?
Invesco NASDAQ Biotech UCITS ETF, SBIO, is provided by Invesco. Learn more about Invesco here.
What is the current assets under management (AUM) of SBIO?
SBIO oversees €362M in assets as of March 12, 2026.
How has SBIO performed lately?
Based on data from March 12, 2026, SBIO returned -1.90% over the past month, 0.65% over the last three months and 0.69% year-to-date.
What are the latest inflows or outflows for SBIO?
As of March 12, 2026, SBIO recorded net flows of -€4.8M over the last month and -€9.8M year-to-date.
Does SBIO distribute dividends?
SBIO follows a capitalizing, meaning it reinvests income within the fund.
What are the main country or region exposures of SBIO?
As of January 31, 2026, SBIO has significant geographic allocations in USA, United Kingdom and Ireland.
In which sector or theme does SBIO invest in?
As of January 31, 2026, SBIO focuses largely on Health Care.
How many securities does SBIO hold and how diversified is it?
As of January 31, 2026, SBIO holds 262 positions in its portfolio, with 52.04% of assets concentrated in its top 15 holdings.
What are the main positions in SBIO?
As of January 31, 2026, SBIO top three holdings include GILEAD SCIENCES, VERTEX PHARMACEUTICALS and AMGEN-T.
What is the base currency of SBIO?
The base currency of SBIO is USD.
Advertisement
About Trackinsight
Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.
Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.
In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.
This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.
Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.
More about TrackinsightETF TOOLS
PLATFORM
ETF NEWS & RESEARCH
© 2014-2026 Trackinsight SA. All rights reserved.
Privacy policy | Cookie policy | | Terms of use | Imprint
Privacy policy | Cookie policy | | Terms of use | Imprint
